Wall Street brokerages predict that Xenon Pharmaceuticals Inc (NASDAQ:XENE) will announce earnings of ($0.49) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Xenon Pharmaceuticals’ earnings, with estimates ranging from ($0.52) to ($0.45). Xenon Pharmaceuticals posted earnings of ($0.29) per share in the same quarter last year, which would suggest a negative year over year growth rate of 69%. The business is scheduled to issue its next quarterly earnings report on Wednesday, March 4th.

On average, analysts expect that Xenon Pharmaceuticals will report full-year earnings of ($1.66) per share for the current financial year, with EPS estimates ranging from ($1.69) to ($1.63). For the next financial year, analysts anticipate that the business will post earnings of ($1.91) per share, with EPS estimates ranging from ($2.02) to ($1.83). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover Xenon Pharmaceuticals.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.16. The business had revenue of $3.50 million for the quarter.

Several research analysts have weighed in on XENE shares. ValuEngine lowered shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd. Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a report on Saturday, October 26th. Guggenheim started coverage on shares of Xenon Pharmaceuticals in a report on Friday, September 20th. They set a “buy” rating and a $25.00 price objective on the stock. Finally, BidaskClub raised shares of Xenon Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, December 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $17.67.

Shares of XENE traded down $0.71 during mid-day trading on Friday, reaching $13.28. The stock had a trading volume of 90,318 shares, compared to its average volume of 205,769. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.25 and a quick ratio of 8.25. Xenon Pharmaceuticals has a 52-week low of $5.41 and a 52-week high of $14.95. The business’s fifty day moving average is $10.44 and its 200 day moving average is $9.66. The firm has a market cap of $345.61 million, a price-to-earnings ratio of -9.98 and a beta of 1.44.

In other Xenon Pharmaceuticals news, CEO Simon N. Pimstone sold 10,395 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $9.51, for a total value of $98,856.45. Following the completion of the transaction, the chief executive officer now owns 258,122 shares in the company, valued at approximately $2,454,740.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Frank A. Holler sold 7,600 shares of the company’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $9.27, for a total value of $70,452.00. Following the completion of the transaction, the director now directly owns 124,161 shares in the company, valued at $1,150,972.47. The disclosure for this sale can be found here. Insiders sold a total of 23,064 shares of company stock valued at $216,552 in the last three months. 8.35% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Granahan Investment Management Inc. MA raised its position in shares of Xenon Pharmaceuticals by 8.3% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 106,459 shares of the biopharmaceutical company’s stock valued at $959,000 after purchasing an additional 8,200 shares in the last quarter. Tower Research Capital LLC TRC bought a new position in Xenon Pharmaceuticals during the 3rd quarter worth $27,000. California Public Employees Retirement System grew its stake in Xenon Pharmaceuticals by 11.0% during the 3rd quarter. California Public Employees Retirement System now owns 62,255 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 6,150 shares during the last quarter. Supplemental Annuity Collective Trust of NJ bought a new position in Xenon Pharmaceuticals during the 3rd quarter worth $99,000. Finally, NEA Management Company LLC grew its stake in Xenon Pharmaceuticals by 229.8% during the 3rd quarter. NEA Management Company LLC now owns 602,663 shares of the biopharmaceutical company’s stock worth $5,430,000 after buying an additional 419,909 shares during the last quarter. 67.68% of the stock is currently owned by institutional investors.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.

See Also: What are benefits of a growth and income fund?

Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.